Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6102455 | 0.87 | AKT1 (0.49) | MAPK14ALDH1A1 | |
| SCHEMBL5260974 | 0.86 | PTGS2 (0.52) | PTGS2PTGS1PI4KBALDH1A1 | |
| SCHEMBL5263570 | 0.85 | MAPK14 (0.39) | PTGS2PTGS1MAPK14ALDH1A1 | |
| SCHEMBL5261869 | 0.85 | AKT1 (0.39) | PTGS2PTGS1MAPK14ALDH1A1 | |
| SCHEMBL14340763 | 0.80 | PTGS2 (0.61) | PTGS2PTGS1MAPK14 | |
| SCHEMBL7215338 | 0.79 | PTGS2 (0.46) | PTGS2PTGS1MAPK14 | |
| SCHEMBL5261375 | 0.78 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL7217116 | 0.78 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL5263337 | 0.77 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL7220911 | 0.77 | PTGS2 (0.50) | PTGS2PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660500-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER | S A L V A T LAB SA (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | BRCA1, CCNA1, DPYD | PTGS2 1467/4885PTGS1 596/4885MAPK14 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.